OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer – Markets Insider
|
OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
Markets Insider ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The study … |
|
Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies
Markets Insider Mustang has entered into an exclusive, worldwide licensing agreement with Fred Hutchinson Cancer Research Center (“Fred Hutch”) for the use of a CAR T therapy related to autologous T cells engineered to express a CD20-specific chimeric antigen … |
NH1 News |
US clears breakthrough gene therapy for childhood leukemia
NH1 News “This is a brand new way of treating cancer,” said Dr. Stephan Grupp of Children’s Hospital of Philadelphia, who treated the first child with CAR–T cell therapy — a girl who’d been near death but now is cancer-free for five years and counting. “That’s … Representatives Probe CMS for Further Detail on New CAR–T Therapy Payment AgreementAJMC.com Managed Markets Network Good News: FDA Approves Gene Therapy for Cancer. Bad News: It Costs $475kHealthcare Packaging |